| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $438K | — | — |
| SG&A Expense | $805K | — | +1404.6% |
| Operating Income | -$1.2M | — | -2223.4% |
| Net Income | -$1.2M | — | -1916.5% |
| EPS (Basic) | -$0.07 | — | -483.3% |
| EPS (Diluted) | -$0.07 | — | -483.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.7M | -18.0% | — |
| Current Assets | $6.8M | -19.1% | — |
| Total Assets | $7.4M | -12.7% | — |
| Current Liabilities | $229K | -32.0% | -32.1% |
| Total Liabilities | $352K | +4.6% | +4.4% |
| Stockholders' Equity | $7.0M | -13.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.1M | — | — |
| Investing Cash Flow | -$318K | — | — |
| Financing Cash Flow | -$30K | — | — |
| +2299.0% |